AZN AstraZeneca plc (ADR)

28.53
0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 data due 2019.
AZD3293
Early Alzheimer's disease
Phase 3 data due 1H 2017.
Tralokinumab
Severe, uncontrolled asthma
Phase 3 data due 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data due 2H 2017.
Tagrisso
First-line lung cancer
Phase 3 data due 2018.
Roxadustat - ANDES
Anaemia
Phase 3 data due 2018.
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2017.
Moxetumomab
Cancer - leukaemia
Phase 3 data due 2H 2017.
Lynparza
First-line ovarian cancer
Data presented March 14, 2017 showed significant PFS benefit. PDUFA date under priority review 3Q 2017. Estimate September 28, 2017 assuming 6-month review.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017. Abstract LBA4.
Lynparza
Breast cancer
NDA filed 4Q 2016.
Faslodex
Breast cancer
Phase 3 PFS data mid-2017 and final OS data at the latest in 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 2018.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data due 2H 2017.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2018.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data due 1H 2018.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data 1H 2017.
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
Phase 3 data due 2H 2017.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data due 2018.
Bydureon
Type 2 Diabetes
Phase 3 data due 1Q 2018.
Brilinta (THEMIS)
Type 2 Diabetes
NDA filing 1H or mid 2017.
Bydureon
Autoinjector
Phase 3 data due 2018.
Anifrolumab
Lupus
Phase 2 data 1H 2017.
Acalabrutinib - ACE-LY-004
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Estimate June 9, 2017.
Durvalumab
Bladder cancer
Second CRL issued March 17, 2017.
ZS-9
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Guided in November for a regulatory filing by the end of 2016.
Benralizumab
Severe, uncontrolled asthma

Latest News

  1. Tesaro’s Zejula Flops as H&S Pattern Emerges
  2. What to Expect From European Pharmaceuticals' First Quarter Results
  3. AbbVie's PARP Inhibitor Comes Up Empty
  4. Group launching website to brand region as biotech leader
  5. ($$) Circassia halts allergy programme after failed trials
  6. Could Dow Stock Merck Undercut AstraZeneca In Lung Cancer?
  7. The Mutual Fund That Is a Top 10 Guru
  8. Charts of the day: Amazon shares gain on NFL deal; Deutsche Bank calls boosts Caterpillar, United Rentals; AT&T adds HBO to unlimited plan
  9. Bristol Keeps Up With Merck In Cancer, But Incyte Is True Winner: Analyst
  10. Drug spun off by AstraZeneca shows promise in hot flashes
  11. AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
  12. Blog Coverage AstraZeneca's Lung Cancer Drug Received Full Approval from FDA
  13. 5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them
  14. FDA Approves Astra's Lung Cancer Drug
  15. Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
  16. FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
  17. TAGRISSO® (osimertinib) Receives US FDA Full Approval
  18. Astrazeneca Scores Milestone Victory in Oncology
  19. Keep Trading AstraZeneca From the Long Side